Comment from The Geneva Foundation, HHS-OPHS-2018-0021, HHS-OPHS-2018-0021-0001, N/A
The Geneva FoundationOtherOther
Summary: The commenter has submitted a clinical trial consent form for a Phase 3 study on Ozanimod for Crohn's disease. This is a document submission rather than a comment expressing a position on the proposed federal action.
Induction Study #2 – A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn’s Disease - BAMC